Fibrocor Therapeutics, LP, a Toronto, Canada-based company focused on developing therapeutics targeting fibrotic diseases, raised CDN$2.8m (approx. $2.1m) in funding.
MaRS Innovation provided the funding while Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will provide drug discovery activities in excange of an equity stake.
Co-founded by Dr Richard Gilbert MD, PhD, Canada Research Chair in Diabetic Complications and Head of Endocrinology at St. Michael’s Hospital and Scientist with the hospital’s Keenan Research Centre for Biomedical Science; Dr Darren Yuen, MD, PhD, Nephrologist with St. Michael’s and Scientist with its Keenan Research Centre for Biomedical Science; and Dr Jeff Wrana, PhD, Senior Investigator at Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Fibrocor focuses on developing novel therapeutics that have the potential to prevent, slow and ultimately reverse the course of fibrosis.
Fibrocor Therapeutics is focused on developing disease modifying therapeutics in fibrosis.
The company has already identified a lead program and will partner with Evotec to develop novel molecules with the anticipation of nominating a lead candidate in 2018. In addition, Fibrocor will collaborate with its academic co-founders to expand access to tissue samples to include several relevant tissues, such as lung, liver, kidney, colon and skin. It will seek to identify novel targets and molecular pathways that are identified from and validated in clinical samples from individuals with the targeted disease for follow-on drug discovery and development programs in fibrosis, generating a pipeline of novel therapeutic targets that it will subsequently work with Evotec on.
FinSMEs
17/01/2017